Encompass Health’s first quarter results for 2026 were met with a notably positive market reaction, as the company’s revenue growth outpaced Wall Street expectations. Management attributed the quarter’s performance to robust demand for inpatient rehabilitation services, improved patient discharge outcomes, and effective workforce retention strategies. CEO Mark Tarr emphasized the benefit of low nursing turnover and expanding clinical development programs in supporting operational efficiency, while also noting a 9.4% reduction in premium labor costs compared to last year. These factors, along with ongoing investments in hospital capacity, were called out as the primary forces behind the company’s solid start to the year.
Is now the time to buy EHC? Find out in our full research report (it’s free for active Edge members).
Encompass Health (EHC) Q1 CY2026 Highlights:
- Revenue: $1.59 billion vs analyst estimates of $1.57 billion (9% year-on-year growth, 1.2% beat)
- Adjusted EPS: $1.60 vs analyst estimates of $1.49 (7.1% beat)
- Adjusted EBITDA: $348.8 million vs analyst estimates of $338.6 million (22% margin, 3% beat)
- The company slightly lifted its revenue guidance for the full year to $6.42 billion at the midpoint
- Management slightly raised its full-year Adjusted EPS guidance to $6 at the midpoint
- EBITDA guidance for the full year is $1.37 billion at the midpoint, in line with analyst expectations
- Operating Margin: 19%, in line with the same quarter last year
- Same-Store Sales rose 1.6% year on year (4.4% in the same quarter last year)
- Market Capitalization: $10.42 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Encompass Health’s Q1 Earnings Call
-
Ann Hynes (Mizuho Securities) asked about the impact of recent unit closures on organic volume growth. CFO Douglas Coltharp explained that closures reduced reported growth by about 85 basis points, but emphasized that this impact will diminish as beds are added and volumes consolidate.
-
Matthew Gillmor (KeyBanc) questioned the moderation in same-store discharge growth and the factors constraining occupancy. Coltharp cited high occupancy rates, a mild flu season, and ongoing Medicare Advantage dynamics as the primary drivers, and discussed plans to lower internal occupancy thresholds for expansion.
-
Pito Chickering (Deutsche Bank) inquired about the ceiling for same-store discharge growth given high occupancy and expansion limitations. Coltharp noted that small-format hospitals and ongoing expansions should address most constraints, making the traditional same-store growth metric less relevant as capacity is added.
-
Benjamin Mayo (Leerink Partners) asked about the sustainability of Medicaid directed payments and the approach to share repurchases. Coltharp stated that provider tax impacts are expected to be flat year-over-year and detailed the company’s disciplined capital allocation strategy for buybacks based on leverage and available cash flow.
-
Jared Haase (William Blair) asked about competitive dynamics with skilled nursing facilities and the company’s ability to capture market share. Chief Operating Officer Patrick Tuer emphasized that inpatient rehabilitation facilities provide a higher level of care and expressed confidence in expanding market share as the population ages.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be tracking (1) progress on hospital openings and bed expansions to alleviate occupancy constraints, (2) the rollout and impact of the admit-and-appeal strategy for Medicare Advantage admissions, and (3) the company’s ability to adapt to new regulatory changes such as TEAM and expanded RCD. The pace of capacity additions and regulatory developments will be key markers of execution.
Encompass Health currently trades at $105.36, up from $100 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
